Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a medical technology company focused on developing unique, life-saving medical products, has released an update on its concussion drug-development program. According to the release, in March 2022 the company acquired key intellectual property (“IP”) to a concussion drug, along with all rights to that drug. During the past few months, the company has completed strategic steps to develop the drug, including appointing two new members of the management team with expertise in progressing drugs through the clinical phase and to the market; completing an FDA-required IND in order to move forward with a phase 1 human trial; developing a nanoparticle spray-dried formulation for intranasal delivery to enhance brain uptake; and developing and manufacturing a novel breath-propelled intranasal delivery device along with filing a patent application for that device. Odyssey has also contracted with two world-class research organizations, Avance Clinical Pty Ltd. and Nucleus Networks, to conduct a phase I clinical trial, and completed the phase 1 human clinical trial to show the drug is safe and well tolerated. In addition, the company has raised more than $5 million to support its development efforts.
To view the full press release, visit https://ibn.fm/KTpUY
About Odyssey Health Inc.
Odyssey Health is a medical company with a focus in the area of life-saving medical solutions. Odyssey’s corporate mission is to create, acquire and develop distinct assets, intellectual property, and exceptional technologies that provide meaningful medical solutions. The company is focused on areas that have an identified technological advantage, provide superior clinical utility and have a substantial market opportunity. For more information about the company, please visit www.OdysseyHealthInc.com.
NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork